Displaying drugs 601 - 625 of 8301 in total
Sparsentan
Sparsentan is a dual antagonist of the endothelin type A receptor (ETAR) and the angiotensin II (Ang II) type 1 receptor (AT1R) with a similar affinity for both (9.3 nM for ETAR and 0.8 nM for AT1R).[A257330,L45300] Sparsentan is first in its class and orally active, and was created by...
Approved
Investigational
Matched Description: … approval based on reduction of proteinuria. ... Sparsentan is a dual antagonist of the endothelin type A receptor (ETAR) and the angiotensin ... [L45315] The use of sparsentan may cause hepatotoxicity and embryo-fetal toxicity.[L45300] …
Miltefosine
Miltefosine is a broad spectrum antimicrobial, anti-leishmanial, phospholipid drug that was originally developed in the 1980s as an anti-cancer agent. It is currently the only recognized oral agent used to treat visceral, cutaneous, and mucosal forms of leishmaniasis, a neglected tropical disease. It can be administered topically or orally and...
Approved
Investigational
Matched Description: … It is currently the only recognized oral agent used to treat visceral, cutaneous, and mucosal forms of …
Fezolinetant
Vasomotor symptoms (VMS), more colloquially known as hot flashes or night sweats, are some of the most common symptoms in menopause. With a median duration of 7.4 years, vasomotor symptoms are also the most common reasons why women seek treatments for menopausal issues.[A259591,A259596] Although mostly considered a nuisance, vasomotor symptoms...
Approved
Investigational
Matched Description: … estrogen levels is thought to be the main cause of VMS, as estrogen therapy has been one of the most ... can thus induce the release of GnRH. ... the role of NK3R in the hypothalamic-pituitary-gonadal (HPG) axis. …
Perindopril
Perindopril is a nonsulfhydryl prodrug that belongs to the angiotensin-converting enzyme (ACE) inhibitor class of medications. It is rapidly metabolized in the liver to perindoprilat, its active metabolite, following oral administration. Perindoprilat is a potent, competitive inhibitor of ACE, the enzyme responsible for the conversion of angiotensin I (ATI) to...
Approved
Matched Description: … Perindoprilat is a potent, competitive inhibitor of ACE, the enzyme responsible for the conversion of ... is a nonsulfhydryl prodrug that belongs to the angiotensin-converting enzyme (ACE) inhibitor class of ... ATII regulates blood pressure and is a key component of the renin-angiotensin-aldosterone system (RAAS …
Ginkgo biloba
Ginkgo biloba extract contains a group of terpene lactones (notably, ginkgolides and diterpenes) and ginkgo flavone glycosides (notably, ginkgetin, bilobetin, and sciadopitysin) that have antioxidant and vasoactive properties. Most of the studies that investigate the effect of ginkgo biloba use the standardized extract of Ginkgo biloba (EGb) 761 (EGb761), which...
Approved
Investigational
Nutraceutical
Matched Description: … [A232389] Most of the studies that investigate the effect of _ginkgo biloba_ use the standardized extract ... _Ginkgo biloba_ extract contains a group of terpene lactones (notably, ginkgolides and diterpenes) and ... of _Ginkgo biloba_ (EGb) 761 (EGb761), which was developed by a German pharmaceutical company in 1964 …
Crisaborole
Crisaborole is a novel oxaborole approved by FDA on December 14, 2016 as Eucrisa, a topical treatment of for mild to moderate atopic dermatitis.
This non-steroidal agent is efficacious in improving disease severity, reducing the risk of infection and reducing the signs and symptoms in patients 2 years old and...
Approved
Investigational
Matched Description: … It is currently under development as topical treatment of psoriasis. ... Crisaborole is a novel oxaborole approved by FDA on December 14, 2016 as Eucrisa, a topical treatment of ... This non-steroidal agent is efficacious in improving disease severity, reducing the risk of infection …
Niraparib
Niraparib is an orally active poly (ADP-ribose) polymerase (PARP) inhibitor. By blocking the enzymes responsible for DNA repair, niraparib induces cytotoxicity in cancer cells. Niraparib is selective towards PARP-1 and PARP-2. First approved by the FDA on March 27, 2017, niraparib is used to treat epithelial ovarian, fallopian tube, or...
Approved
Investigational
Dexibuprofen
Dexibuprofen, S(+)-ibuprofen, is a non-steroidal anti-inflammatory drug (NSAID). It is a pharmacologically effective enantiomer of racemic ibuprofen that differs in physicochemical properties. It is proposed to be more pharmacologically active and tolerable with a better safety profile than ibuprofen due to higher concentration of active S enantiomer. Dexibuprofen has a...
Approved
Investigational
Matched Description: … It is a pharmacologically effective enantiomer of racemic ibuprofen that differs in physicochemical properties ... pharmacologically active and tolerable with a better safety profile than ibuprofen due to higher concentration of …
Reslizumab
Reslizumab is a humanized interleukin-5 (IL-5) antagonist monoclonal antibody (IgG4 kappa) that is produced by recombinant DNA technology in murine myeloma non-secreting 0 (NS0) cells. IL-5 is a pro-inflammatory cytokine that is responsible for the growth and differentiation, recruitment, activation, and survival of eosinophils [FDA Label]. Elevated levels of eosinophils...
Approved
Investigational
Matched Description: … and nonallergic forms of asthma where eosinophilia is prominent. ... cytokine that is responsible for the growth and differentiation, recruitment, activation, and survival of ... Elevated levels of eosinophils increase the risk for asthma exacerbations, including both allergic forms …
Abatacept
Abatacept is a soluble fusion protein, which links the extracellular domain of human cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) to the modified Fc (hinge, CH2, and CH3 domains) portion of human immunoglobulin G1 (IgG1).[L20504,L42715] Structurally, abatacept is a glycosylated fusion protein with a MALDI-MS molecular weight of 92,300 Da and it...
Approved
Matched Description: … 92,300 Da and it is a homodimer of two homologous polypeptide chains of 357 amino acids each. ... formulation of CTLA4-Ig into clinical trials (RG2077). ... antigen 4 (CTLA-4) to the modified Fc (hinge, CH2, and CH3 domains) portion of human immunoglobulin …
Avelumab
Avelumab is a human IgG1 lambda monoclonal antibody that binds programmed cell death ligand-1 (PD-L1) to block its interaction with its receptors found on T cells and antigen-presenting cells. Avelumab was first approved by the FDA on March 23, 2017. On September 18 and December 18 of the same year,...
Approved
Investigational
Matched Description: … It is used in the treatment of Merkel cell carcinoma, metastatic urothelial carcinoma, or renal cell ... [A261496] On September 18 and December 18 of the same year, it was also granted approval by EMA [L48126 …
Tirbanibulin
Tirbanibulin (KX-O1 or KX2–391) is a dual inhibitor of Src Kinase and tubulin. On December 14, 2020, tirbanibulin was approved by the FDA for the topical treatment of actinic keratosis on the face or scalp. It is marketed under the brand name Klisyri. Actinic keratosis is a chronic condition characterized...
Approved
Investigational
Matched Description: … Tirbanibulin (KX-O1 or KX2–391) is a dual inhibitor of Src Kinase and tubulin. ... [A225726] On December 14, 2020, tirbanibulin was approved by the FDA for the topical treatment of actinic ... Tirbanibulin blocks the molecular pathways that promote the proliferation, survival, and metastasis of …
Clofarabine
Clofarabine is a purine nucleoside antimetabolite that is being studied in the treatment of cancer. It is marketed as Clolar in the U.S. and Canada, or Evoltra in Europe, Australia, and New Zealand. Clofarabine is used in paediatrics to treat a type of leukaemia called relapsed or refractory acute lymphoblastic...
Approved
Investigational
Matched Description: … leukaemia (ALL), only after at least two other types of treatment have failed. ... Clofarabine is a purine nucleoside antimetabolite that is being studied in the treatment of cancer. ... Clofarabine is used in paediatrics to treat a type of leukaemia called relapsed or refractory acute lymphoblastic …
Galcanezumab
Galcanezumab is a humanized monoclonal antibody developed by Eli Lilly and Company against human calcitonin gene-related peptide (CGRP). Although several small-molecule CGRP receptor antagonists have been developed, humanized monoclonal antibodies like galcanezumab are specifically designed to selectively bind to CGRP entities with high potency. Given this target specificity, lack of...
Approved
Investigational
Matched Description: … migraine and the treatment of episodic cluster headache. ... Galcanezumab was approved by the FDA in September 2018, and is indicated for the preventive treatment of ... [A33112] Given this target specificity, lack of off-target toxicity, and characteristic proteolysis profile …
Phentolamine
Phentolamine is a reversible, non-selective alpha-adrenergic blocker that induces vasodilation. While initially introduced to the market for the treatment of hypertension, this clinical use was halted due to cardiovascular and gastrointestinal adverse effects with the prolonged use of large oral doses of phentolamine.[A261781, A261786] It has several therapeutic uses, including...
Approved
Matched Description: … of phentolamine. ... prevention of norepinephrine-induced extravasation, diagnosis of pheochromocytoma, reversal of soft-tissue ... anesthesia, and treatment of pharmacologically-induced mydriasis. …
Dabrafenib
Dabrafenib mesylate (Tafinlar) is a reversible ATP-competitive kinase inhibitor and targets the MAPK pathway. It was approved on May 29, 2013, for the treatment of melanoma with V600E or V6000K mutation. It was also used for metastatic non-small cell lung cancer with the same mutation. In May 2018, Tafinlar (dabrafenib),...
Approved
Investigational
Matched Description: … It was approved on May 29, 2013, for the treatment of melanoma with V600E or V6000K mutation. …
Leuprolide
Leuprolide is a synthetic 9-residue peptide analogue of gonadotropin-releasing hormone (GnRH). Unlike the endogenous decapeptide GnRH, leuprolide contains a single D-amino acid (D-leucyl) residue, which helps to increase its circulating half-life from three to four minutes to approximately three hours. As a GnRH mimic, leuprolide is capable of binding to...
Approved
Investigational
Matched Description: … Prolonged activation of GnRHR results in significant downregulation of sex steroid levels, which is primarily ... downstream modulation of both gonadotropin hormone and sex steroid levels. ... Leuprolide is a synthetic 9-residue peptide analogue of gonadotropin-releasing hormone (GnRH). …
Thyrotropin alfa
Thyrotropin alfa is a recombinant form of thyroid stimulating hormone used in performing certain tests in patients who have or have had thyroid cancer. It is also used along with a radioactive agent to destroy remaining thyroid tissue in certain patients who have had their thyroid gland removed because of...
Approved
Vet approved
Matched Description: … The alpha subunit of thyrotropin alfa, which is the effector region responsible for the stimulation of ... of 92 amino acid residues containing two N-linked glycosylation sites and a beta subunit of 112 residues ... The amino acid sequence of thyrotropin alfa is identical to that of human pituitary thyroid stimulating …
Naproxen
Naproxen is classified as a nonsteroidal anti-inflammatory dug (NSAID) and was initially approved for prescription use in 1976 and then for over-the-counter (OTC) use in 1994. It can effectively manage acute pain as well as pain related to rheumatic diseases, and has a well studied adverse effect profile. Given its...
Approved
Vet approved
Matched Description: … overall tolerability and effectiveness, naproxen can be considered a first line treatment for a variety of ... combination with sumatriptan to treat migraines, and in combination with esomeprazole to lower the risk of …
Sodium aurothiomalate
Sodium aurothiomalate is a gold compound that is used for its immunosuppressive anti-rheumatic effects. Gold Sodium Thiomalate is supplied as a solution for intramuscular injection containing 50 mg of Gold Sodium Thiomalate per mL. It is most effective in active progressive rheumatoid arthritis and of little or no value in...
Approved
Investigational
Matched Description: … of extensive deformities or in the treatment of other forms of arthritis. ... Gold Sodium Thiomalate is supplied as a solution for intramuscular injection containing 50 mg of Gold ... It is most effective in active progressive rheumatoid arthritis and of little or no value in the presence …
Atoltivimab
Ebola virus (EBOV) remains an important human pathogen within the Ebolavirus genus, having been responsible for at least 17 known outbreaks with an average case fatality rate of 43.92%. Immune therapy using monoclonal antibodies (mAbs) is becoming an increasingly attractive therapeutic method to combat infectious diseases due to its rapid...
Approved
Matched Description: … antibodies were important for therapeutic benefit in animal models of EBOV infection. ... _ genus, having been responsible for at least 17 known outbreaks with an average case fatality rate of ... [A222078] The chief surface target of EBOV particles is the GP1,2 glycoprotein, which also …
Maftivimab
Ebola virus (EBOV) remains an important human pathogen within the Ebolavirus genus, having been responsible for at least 17 known outbreaks with an average case fatality rate of 43.92%. Immune therapy using monoclonal antibodies (mAbs) is becoming an increasingly attractive therapeutic method to combat infectious diseases due to its rapid...
Approved
Matched Description: … antibodies were important for therapeutic benefit in animal models of EBOV infection. ... _ genus, having been responsible for at least 17 known outbreaks with an average case fatality rate of ... [A222078] The chief surface target of EBOV particles is the GP1,2 glycoprotein, which also …
Deflazacort
Deflazacort, also known as Emflaza, is a corticosteroid prodrug used as an agent to manage Duchenne Muscular Dystrophy (DMD). It is marketed by Marathon Pharmaceuticals and was approved in February 2017 by the FDA.[L6694,FDA label]
Duchenne Muscular Dystrophy is an inherited disorder resulting from mutations of the dystrophin gene, which...
Approved
Investigational
Matched Description: … [L6694,FDA label]
Duchenne Muscular Dystrophy is an inherited disorder resulting from mutations of ... weakness and progressive breathing and cardiovascular disability, severely impacting patient quality of ... [A179449]
Deflazacort delays the onset of muscle related complications resulting from DMD[A179455] …
Polatuzumab vedotin
Polatuzumab vedotin is a CD79b-directed antibody-drug conjugate that delivers monomethyl auristatin E (MMAE), an anti-mitotic agent, to cancer cells. The drug consists of three components - a humanized immunoglobulin G1 (IgG1) monoclonal antibody specific for human CD79b (polatuzumab), MMAE, and protease-cleavable linker called maleimidocaproyl-valine-citrulline-p-aminobenzyloxycarbonyl (mc-vc-PAB) that covalently attaches MMAE to...
Approved
Investigational
Matched Description: … [L6658] The drug consists of three components - a humanized immunoglobulin G1 (IgG1) monoclonal antibody …
Eplerenone
Eplerenone, an aldosterone receptor antagonist similar to spironolactone, has been shown to produce sustained increases in plasma renin and serum aldosterone, consistent with inhibition of the negative regulatory feedback of aldosterone on renin secretion. The resulting increased plasma renin activity and aldosterone circulating levels do not overcome the effects of...
Approved
Matched Description: … the negative regulatory feedback of aldosterone on renin secretion. ... shown to produce sustained increases in plasma renin and serum aldosterone, consistent with inhibition of ... resulting increased plasma renin activity and aldosterone circulating levels do not overcome the effects of …
Displaying drugs 601 - 625 of 8301 in total